ReviewTherapie
Diabetes and COVID-19.
Review in Therapie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Severity of SARS-CoV-2 Illness in Patients With Type 1 and Type 2 Diabetes Mellitus.HCA healthcare journal of medicine · 2025Article
- γ' fibrinogen levels as a biomarker of COVID-19 respiratory disease severity.Blood cells, molecules & diseases · 2023Article
- Type 2 diabetes prevalence, awareness, and risk factors in rural Mali: a cross-sectional study.Scientific reports · 2023Article
- Examining the Determinants of COVID-19 Severity: A Cohort Study in Morocco of 915 Patients.Cureus · 2022Article
- Retrospective study on the impact of COVID-19 lockdown on patients with type 2 diabetes in Northern Jordan.BMJ open · 2022Article
- Gamma' fibrinogen levels as a biomarker of COVID-19 respiratory disease severity.Research square · 2022Article
- The Pathophysiology and Management of Diabetic Ketoacidosis in COVID-19 Patients: a Literature Review.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2022Article
- COVID-19 Impact on Public Health, Environment, Human Psychology, Global Socioeconomy, and Education.TheScientificWorldJournal · 2022Review
- Does DPP-4 inhibitor treatment affect the clinical outcomes of COVID-19 in type 2 diabetes mellitus patients?Northern clinics of Istanbul · 2022Article
- Evaluation and management of COVID-19-related severity in people with type 2 diabetes.BMJ open diabetes research & care · 2021Article
- Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications.European geriatric medicine · 2021Review
- Diabetes Mellitus-A Risk Factor for Unfavourable Outcome in COVID-19 Patients-The Experience of an Infectious Diseases Regional Hospital.Healthcare (Basel, Switzerland) · 2021Article
- Oral high dose vitamin D for the treatment of diabetic patients with COVID-19: A protocol for systematic review and meta-analysis.Medicine · 2021Article
- What Every Diabetologist Should Know about SARS-CoV-2: State of Knowledge at the Beginning of 2021.Journal of clinical medicine · 2021Review
- Practical considerations for pregnant women with diabetes and severe acute respiratory syndrome coronavirus 2 infection.American journal of obstetrics & gynecology MFM · 2020Article
- Article
- Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to previous reports, diabetes seems to be a risk factor which worsens the serious clinical events caused by COVID-19. But is diabetes per se a risk factor that increases the probability of getting the virus? This paper will discuss this point. There are not many research data on antidiabetic drugs in this context. The potential influence of glucose-lowering agents on the severity of COVID-19 has not been described yet. Dipeptidylpeptidase-4 (DPP-4) is a cell surface protein ubiquitously expressed in many tissues and it is also a soluble molecule found in serum/plasma fluids. DPP-4 is involved in infection of cells by some viruses. This paper reviews data about the use of DPP-4 inhibitors and others diabetes drugs on COVID-19 patients. As such, no available evidence has yet suggested that glucose-lowering drugs - including those targeting DPP4-related pathways - produce any significant harm or benefit in the context of human infections. However, insulin must remain the first-choice agent in the management of critically ill-hospitalized patients, while it is recommended to suspend other agents in unstable patients. This paper provides related French and international recommendations for people with diabetes who got infected by COVID-19 and upholds that infections may alter glucose control and may require additional vigilance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.